Osaikang forced Hengrui to win 2 billion

On January 18, NMPA's official website updated the information on approved drugs, and Osaikang's application for the market listing of injections of 3 types of tymoamine was approved and evaluated as such.
January 2019, Hengrui announced that the company's injection of 3 types of tymoamine imitation was approved and won the domestic first imitation.
, the capsules and injections of tamoamine have been evaluated by two enterprises, and the oral regular release dosage form has been included in the fourth batch of national collection catalog.
Figure 1: Osaikang's injection of thymosamine approved Information Source: NMPA Official Website Figure 2: Sales of tymoamine Source: Minet China's public medical institutions terminal competition pattern is known to be a type of methamphetamine and diazine with anti-tumor activity alkanes The drug can be used to treat newly diagnosed adult patients with polyglioblastoma, starting with radiotherapy and then as maintenance therapy, or to treat adult patients with resusctic interdessional astroma, such as those who progress after treatment with a routine program containing nitrosine and methamphetamine. According to
meters of intranet data, since 2018 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of this variety has exceeded 2 billion yuan, a growth rate of 17.89 percent, the last two years of growth has slowed.
January 4, 2019, Hengrui announced that the company's declared injection of 3 types of imitations of tymoamine was approved and evaluated, successfully won the domestic first imitation, the product project investment in research and development costs of about 6.79 million yuan.
Table 1: Currently reviewed tymoamine-related products Source: Minet MED2.0 China Drug Review Database Currently in the domestic market, tymoamine capsules and injections have been approved for listing, capsule evaluation enterprises Tianshili, Shuangli Pharmaceuticals, and has been included in the fourth batch of national collection catalog, will be the original study of Merca East to start a price war, and injections in addition to Hengrui Medicine, Osaikang also according to the new classification was approved as the same evaluation.
the product is also the first new product approved by Osaikang in 2021, and the company currently has one new class 2.2 drug, eight generic drugs listed under the new classification (class 3, category 4) in the review and approval.
source: NMPA official website, Minet database review data statistics as of January 18, 2021, if there are errors, please point out.